CA

CanBas Co.,Ltd.

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.

4575 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CanBas Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on discovering and developing innovative oncology drugs, particularly in the field of immuno-oncology, that target the cell cycle. CanBas utilizes a proprietary screening system to advance its drug pipeline, which includes the clinical-stage candidate CBP501, a calmodulin-modulating peptide. A key objective of its research is to create anticancer treatments with fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:46
Regulatory News Service
確認書
Japanese 8.1 KB
2025-09-29 08:46
Annual Report
有価証券報告書-第26期(2024/07/01-2025/06/30)
Japanese 576.6 KB
2025-02-13 07:55
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-02-13 07:54
Interim Report
半期報告書-第26期(2024/07/01-2025/06/30)
Japanese 160.4 KB
2024-09-30 08:04
Post-Annual General Meeting Information
臨時報告書
Japanese 22.7 KB
2024-09-27 08:21
Governance Information
内部統制報告書-第25期(2023/07/01-2024/06/30)
Japanese 21.7 KB
2024-09-27 08:21
Registration Form
確認書
Japanese 8.1 KB
2024-09-27 08:20
Annual Report
有価証券報告書-第25期(2023/07/01-2024/06/30)
Japanese 637.2 KB
2024-05-10 08:16
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-10 08:16
Quarterly Report
四半期報告書-第25期第3四半期(2024/01/01-2024/03/31)
Japanese 134.6 KB
2024-02-09 08:13
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-09 08:12
Interim Report
四半期報告書-第25期第2四半期(2023/10/01-2023/12/31)
Japanese 163.0 KB
2023-11-10 08:00
Regulatory News Service
確認書
Japanese 8.0 KB
2023-11-10 07:51
Quarterly Report
四半期報告書-第25期第1四半期(2023/07/01-2023/09/30)
Japanese 134.0 KB
2023-09-27 08:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.